A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

In this clinical trial, participants with episodic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine days with Xeomin injections compared to Placebo injections. Trial details include: * Trial duration: 52 to 55 weeks; * Screening period: 4 to 5 weeks; * Treatment duration: 4 treatments, each about 12 weeks apart; and * Visit frequency: about every 4 weeks, 14 visits in total. The first and last visit and the 4 treatment visits are on-site, the other 8 visits are remote by phone / video call.

NCT Number	NCT07018700
Lead Sponsor	Merz Therapeutics GmbH
Conditions	Episodic Migraine
Enrollment	990 participants
Start Date	2025-08-21
Primary Completion	2027-03 (estimated)
Study Completion	2027-10 (estimated)
Updated on ClinicalTrials.gov	2026-06-25